Benzinga | Apr 5, 2021 07:09AM EDT

uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington's disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year.